IP Library Granted Patent US 10,543,286
Granted Patent B2
US 10,543,286 · App. 15/765,317 · Granted Jan 28, 2020

Methods for increasing platelet count by inhibiting biliverdin IXβ reductase

Inventors: Wadie F. Bahou (Setauket, NY); Song Wu (Stony Brook, NY)
Assignee: The Research Foundation for The State University of New York
A61K48/0066A61K35/19A61K48/0016A61K48/0083A61P7/02C12Y103/01024
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,543,286
App. No.
15/765,317
Granted
Jan 28, 2020
Kind
B2
Abstract

The present disclosure provides methods of treating a human having a disease or disorder that would benefit from increasing platelet counts. The method involves inhibiting the enzyme activity of biliverdin IXβ reductase (BLVRB) activity or inhibiting the expression of BLVRB gene.

Claims (15)

1. A method of increasing platelet counts of a subject, the method comprising:

administering to the subject therapeutically effective amount of an agent that inhibits biliverdin IXβ reductase (BLVRB) enzymatic activity, wherein the agent is 4-((6-Chloro-2-methoxyacridin-9-yl)amino)-2-((4-methylpiperazin-1-yl)methyl)phenol and wherein the agent increases the platelet count of the subject.

2. The method of claim 1 , wherein the BLVRB enzymatic activity is inhibited by at least about 30% to about 100%.

3. A method of increasing platelet counts of a subject, the method comprising:

administering to the subject therapeutically effective amount of an agent that inhibits biliverdin IXβ reductase (BLVRB) enzymatic activity and increases the platelet count of the subject.

4. The method of claim 1 , wherein the agent is administered at a dose of about 0.01 mg/kg to about 50 mg/kg.

5. The method of claim 1 , wherein the inhibition of BLVRB enzymatic activity or BLVRB gene expression leads to increased thrombopoiesis.

6. The method in claim 1 , wherein the inhibition of BLVRB enzymatic activity or BLVRB gene expression leads to accumulation of reactive oxygen species (ROS).

7. The method of claim 3 , wherein decreased production of platelets is caused by chemotherapy.

8. The method of claim 1 wherein the subject is a human.

9. The method of claim 1 wherein the subject is an animal.

10. The method of claim 3 , wherein the agent is administered at a dose of about 100 mg/kg.

11. The method of claim 3 , wherein the agent is 4-((6-Chloro-2-methoxyacridin-9-yl)amino)-2-((4-methylpiperazin-1-yl)methyl)phenol.

12. The method of claim 3 wherein the subject is a human.

13. The method of claim 3 wherein the subject is an animal.

Assignments (2)
CONFIRMATORY LICENSE Recorded May 10, 2018
From: STATE UNIVERSITY NEW YORK STONY BROOK
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046125/0099 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2018
From: BAHOU, WADIE F.; WU, SONG
To: THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
Reel/Frame 045408/0596 →
Continuity (2)
Provisional Application 62238236 · Oct 7, 2015
Related Publication 20180303958A1 · Oct 25, 2018